🇺🇸 FDA
Pipeline program

TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone

NMPA 2018L02262/2018L02263

Phase 2 small_molecule active

Quick answer

TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone for Prostatic Neoplasms, Castration-Resistant is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Prostatic Neoplasms, Castration-Resistant
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials